HOME >> BIOLOGY >> NEWS
Double trouble: Cells with duplicate genomes can trigger tumors

BOSTON--Abnormal cell division that yields cells with an extra set of chromosomes can initiate the development of tumors in mice, researchers at Dana-Farber Cancer Institute have shown, validating a controversial theory about cancer causation put forth by a scientific visionary nearly 100 years ago.

The so-called "double-value" cells are produced by random errors in cell division that occur with unknown frequency. The generation of these genetically unstable cells appears to be a "pathway for generating a tumor," says David Pellman, MD, a pediatric oncologist at Dana-Farber and at Children's Hospital Boston. He is the senior author on a report in the Oct. 13 issue of Nature. Takeshi Fujiwara, PhD, and Madhavi Bandi of Dana-Farber, are the paper's co-first authors.

The research was performed in experimental animals, but such "double-value" cells are seen in a variety of early human cancers and in a precancerous condition called Barrett's esophagus. In addition to the extra chromosomes, the "double value" or "tetraploid" cells also duplicate a cell structure called the centrosome that plays a role in maintaining a stable genome. The extra centrosomes may be at the root of the cancer-triggering process. Once the genetic instability sets in, tumors "evolve " by losing, gaining and rearranging chromosomes.

Late-stage tumors commonly have too many centrosomes and a near triploid chromosome number (one and a half times the normal chromosome content). Because the cells with extra chromosomes and centrosomes are biologically different from normal cells, cancer drugs designed to kill them while sparing normal cells are "an interesting possibility," says Pellman, who is also an associate professor of Pediatrics at Harvard Medical School.

The researchers treated normal breast cells with a compound that interfered with the final step of cell division, causing many of them to have the extra chromosome set. To make the cells more likely to become mali
'"/>

Contact: Janet Haley Dubow or Richard Saltus
janet_haley@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
12-Oct-2005


Page: 1 2 3

Related biology news :

1. Double identities lie behind chromosome disorders
2. Double honors for diabetes researchers
3. Double honor recognises world-class science and spin-out success
4. Double trouble for RA patients: PLC-gamma-2 regulates osteoclastogenesis and B cell differentiation
5. Double-trouble: Cells with duplicate genomes can trigger tumors
6. Double triumph in stem cell quest
7. Cells take risks with their identities
8. Cells re-energize to come back from the brink of death
9. Need oxygen? Cells know how to spend and save
10. Cells selectively absorb short nanotubes
11. Cells use noise to make cell-fate decisions

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Double trouble Cells with duplicate genomes can trigger tumors

(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma ... company developing therapeutic products for rare disorders, announced today ... being held in San Francisco, CA. ... and Chief Executive Officer, will present on Monday, January ... The presentation will be webcast live and may be ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: